That LIR treatment had no reducing effect on these normal blood glucose levels of our experimental rats is not surprising, as it is shown that incretins do only reduce blood glucose levels in individuals with high plasma glucose concentrations, such as people with type II diabetes, and not in normoglycemic people (Vella et al. 2002). This evidence concerns the gene GCG and type 2 diabetes mellitus.